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Background: In previous studies we found that MHC2TA +1614 genotype frequency was very different when MS
patients with and without human herpesvirus 6 (HHV-6) in serum samples were compared; a different clinical
behavior was also described. The purpose of the study was: 1. To evaluate if MHC2TA expression in MS patients was
influenced by interferon beta (IFN-beta) treatment. 2. To study MHC2TA expression in MS patients with and without
minor allele C. 3. To analyze the relation between MHC2TA mRNA levels and HHV-6 active infection in MS patients.
Methods: Blood and serum samples of 154 MS patients were collected in five programmed visits: basal (prior to
beginning IFN-beta treatment), six, twelve, eighteen and twenty-four months later. HHV-6 in serum and MHC2TA
mRNA levels were evaluated by PCR and RT-PCR, respectively. Neutralizing antibodies (NAbs) against IFN-beta were
analyzed by the cytopathic effect assay.
Results: We found that MHC2TA mRNA levels were significantly lower among MS patients with HHV-6 active
infection at the basal visit (without treatment) than in those MS patients without HHV-6 active infection at the basal
visit (p = 0.012); in all the positive samples we only found variant A. Furthermore, 58/99 (58.6%) MS patients without
HHV-6 along the five programmed visits and an increase of MHC2TA expression after two-years of IFN-beta
treatment were clinical responders vs. 5/21 (23.8%) among those MS patients with HHV-6 and a decrease of
MHC2TA mRNA levels along the two-years with IFN-beta treatment (p = 0.004); no differences were found between
patients with and without NAbs.
Conclusions: MHC2TA mRNA levels could be decreased by the active replication of HHV-6; the absence of HHV-6
in serum and the increase of MHC2TA expression could be further studied as markers of good clinical response to
IFN-beta treatment.
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In a previous study in the Spanish multiple sclerosis
(MS) population, our group found that the MHC2TA
+1614 genotype frequency was very different when MS
patients with human herpesvirus 6 (HHV-6) were com-
pared with MS patients without this virus [1]. The pro-
portion of carriers of the minor allele (C) was higher in* Correspondence: ralvarezlafuente@yahoo.es
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distribution, and reproduction in any mediumMS patients with HHV-6 than in patients without HHV-
6, and then in controls. These results provided the
evidence of an interaction between genetic and environ-
mental factors that might lead to MS by an unknown
mechanism. In a subsequent study [2], we verified the
previous association that we had found between the
HHV-6 active replication and the presence of MHC2TA
rs4774C; furthermore, we found that those MS patients
with minor allele C and HHV-6 active infection had dif-
ferent clinical behavior since they were worse clinical
responders to IFN-beta treatment, and they had a higher
progression in the first two years of the disease.ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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MHC2TA rs4774C could be possible markers of IFN-
beta response.
In order to deepen this possible relationship we per-
formed a new study with the following objectives: 1. To
evaluate if MHC2TA expression in MS patients was
influenced by interferon beta (IFN-beta) treatment. 2.
To study MHC2TA expression in MS patients with and
without minor allele C. 3. To analyze the relation be-
tween MHC2TA mRNA levels and HHV-6 active infec-
tion in MS patients.
Methods
Subjects
A total of 154 patients with clinically definite relapsing-
remitting MS (RRMS) were included in the study
(53 males, age ranging between 21-58 years, and 101
females, age ranging between 20-57 years). All patients
were characterized as having RRMS for more than 2
years. All of them had been treated, at least, during two
years, with interferon beta: IFN-beta-1a (Avonex, n = 15)
30 μg intramuscularly once weekly, IFN-beta-1b (Beta-
feron, n = 88) 8 MIU subcutaneously every other day, or
IFN-beta-1a (Rebif, n = 51) 22 or 44 μg subcutaneously
three times weekly, for more than two years. A control
group of 154 healthy Spanish individuals was included
for comparative purposes in the expression study. RRMS
patients and controls were paired by age and sex; none
of the healthy controls had relatives of first or second
degree with MS or other autoimmune diseases, and
none of them had received antiviral medication for at
least 6 months before the enrolment in the study. The
study conformed to the Helsinki Declaration and was
approved by the local ethic committee (“Comité Ético de
Investigación Clínica del Hospital Clínico San Carlos”),
and all the participants received and signed the written
informed consent before the enrolment.
Collection of clinical data
The following clinical data were collected: number of
relapses in the first two years of treatment, EDSS in the
first two years of treatment, and response to IFN-beta
treatment. We considered that clinical responders were
those MS patients without EDSS progression and with-
out relapses in the first two years of treatment with IFN-
beta. Definition of progression was different depending
on the pre-treatment EDSS score: 1) increase ≥ 1.5 points
if pre-treatment EDSS = 0; 2) increase ≥ 1 point if pre-
treatment EDSS ≥ 1 and≤ 5; 3) increase ≥ 0.5 points if
pre-treatment EDSS ≥ 5.5.
Collection of samples
At the time of visit 10 ml of peripheral blood were drawn
by vein puncture into sterile tubes with EDTA anddirectly used for DNA extraction, and 2 ml of serum were
isolated in serum separator tubes by centrifugation and
then were separate into aliquots and stored at –80°C.
Among RRMS patients, two samples, blood and serum,
were collected at the basal visit (before starting IFN-beta
treatment), and a second pair of samples were obtained
six (ranged 5-7), twelve (ranged 11-13), eighteen (ranged
16-20), and twenty-four months (ranged 22-26) after
starting IFN-beta treatment.
DNA extraction
Total DNA was isolated by DNA spin column technique
of QIAamp DNA Blood Mini Kit (QIAGEN. Hilden.
Germany), from 0.2 ml of blood, and QIAamp Ultrasens
Virus Kit (QIAGEN), from 1 ml of serum, according to
the manufacturer’s instructions. Each sample was
extracted in duplicate. Two negative controls, consisting
of reagents only, were processed with each set of eight
samples.
MHC2TA Genotyping
One polymorphism in the MHC2TA gene (rs4774) was
analyzed by TaqMan Assay-on-Demand (C___381733_10)
from Applied Bios stems, following manufacturer’s
suggestions. This genetic marker conformed to Hardy-
Weinberg equilibrium proportions in the control popula-
tion (p > 0.05).
Quantitative real-time PCR for HHV-6
PCR assays were performed in a Rotor-Gene 3000
(Corbett Research. Sydney. Australia). Primers and
probes for detection of HHV-6 and PCR protocol are
previously published [3].
HHV-6 variant detection
HHV-6 variants (A and B), were characterized in the
HHV-6 positive samples by quantitative PCR, as previ-
ously described [4].
RNA extraction
Total RNA was extracted from peripheral blood using
the QIAamp RNA Blood Mini Kit (QIAGEN. Hilden.
Germany) following manufacturer instructions. Prior to
RT, all the samples were digested with RNase-free
DNase (Sigma, St. Louis. MO. USA), at 70°C for 15 min,
to avoid any possible DNA contamination.
Reverse transcription (RT)
RT was carried out with the Transcript or first strand
cDNA synthesis kit (Roche Diagnostics, S.L. Barcelona.
Spain). A 25°C incubation was followed by one cycle of
50°C for 1 hour and 1 cycle of 85°C for 5 minutes to in-
activate the reaction and the cDNA was stored at –80°C
until used for quantitative real-time PCR.
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To measure MHC2TA mRNA expression, quantitative
real-time PCR was performed with a TaqManW Gene Ex-
pression Assay ID Hs00172106_m1 from Applied Bios
stems (Foster City. CA. USA), following the manufac-
turer instructions. As MHC2TA transcriptional expres-
sion was expressed in a relative manner, the results were
normalized using the housekeeping gene beta-actin as
reference to avoid differences due to possible RNA deg-
radation/contamination or different reverse transcription
efficiency (Beta-actin control kit. Eurogentec. Liege. Bel-
gium), as it has been previously described [5]. Results
were normalized to normalization standard samples of
cDNA obtained from matched healthy controls, run at
the same time as the cDNA samples of the experimentalFigure 1 MHC2TA expression levels as NR. A. Mean NR at each visit. B.
C. MS patients with minor allele C and HHV-6 in serum at basal visit vs. MS
basal visit.points; these controls were assigned the normalization
ratio (NR) of 1.
Cytopathic effect (CPE) assay
NAbs were measured through a CPE assay using the
encephalomyocarditis (EMC) murine virus [6] on human
lung carcinoma cell line (A549). Monolayers of A549
cells were prepared in 96 wells plates. Serum samples
were inactivated at 56°C for 30 min. Then, they were
diluted and incubated for 1 hour with IFN-beta 1b at a
final concentration of 10 U/ml, in order to allow the
joint of NAbs to IFN-beta. After that, the mixture was
added to the plates with A549 cells monolayers and
incubated overnight. Cells were then infected with EMC
murine virus and viable cells were quantified 24 hoursMS patients with minor allele C vs. MS patients without minor allele C.
patients without minor allele C and without HHV-6 active infection at
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Acetic acid 33% was added to the plates and absorbance
at 620 nm was measured. The titres were calculated
according to Kawade’s formula [7], and expressed in ten-
fold reduction unit (TRU). Samples were considered
positives if titres were > 20.
Statistical analysis
Odds ratios (O.R.) and exact 95 percent confidence
intervals (C.I.) were calculated with standard microcom-
puter software: Epi Info v. 6.02 (CDC, Atlanta, USA)
and SPSS Ver. 15.0 (SPSS Inc.). The chi-square test was
used to compare qualitative variables. As MHC2TA ex-
pression levels (NR) were not normally distributed we
used non- parametric tests for its analysis: Kruskal-
Wallis method for comparison of more than two groups
and U-Mann Whitney test to compare NRs between two
groups. We considered statistically significant differences
when p < 0.05.
Results
The NAbs prevalence along the two years follow-up
was 22.1% (34/154): 6.7% for MS patients treated with
Avonex (1/15), 11.8% for MS patients treated with Rebif
(6/51) and 30.7% among MS patients treated with Beta-
feron (27/88). At the six month visit the NAbs preva-
lence was 9.7% (15/154), 13.6% at the twelve month visit
(21/154), 17.5% at 18-month visit (27/154) and 16.2%
two years after the beginning of the treatment (25/154).
When we analyzed the influence of IFN-beta treat-
ment on the expression of MHC2TA gene in the whole
MS population, we did not find any statistical significant
difference between the basal visit and the 24-month visit
(p = 0.134): mean NR was 1.4 at basal visit, 1.3 after six
months of treatment, 1.5 twelve months later, 1.8 at the
18-month visit, and 2.1 two years later after starting
IFN-beta treatment (Figure 1A). No statistical significant
differences were found between MS patients with and
without NAbs.
When we studied MHC2TA expression in MS patients
with and without minor allele C (82 MS patients were
GG genotype, 64 were GC genotype, and 8 were CC
genotype), we did not find any statistical significant dif-
ference for any of the scheduled visits: we found NRs of
1.6, 1.5, 1.8, 2, and 2.2 for the basal visit and 6, 12, 18Table 1 HHV-6 DNA prevalence along the five scheduled visit
VB 6M
HHV-6 DNA prevalence in serum 28 / 154 22 / 15
18.2% 14.3%
p (between the basal visit and the 24-month visit)
OR (between the basal visit and the 24-month visit)and 24 months later, respectively, among MS patients
with minor allele C, and NRs of 1.2, 1.1, 1.3, 1.7, and 2
for the basal visit and 6, 12, 18 and 24 months later, re-
spectively, among MS patients without minor allele C
(Figure 1B); MS patients with allele C were normalized
with healthy subjects with allele C, and MS patients
with allele G were normalized with healthy subjects with
allele G.
A total of 36 MS patients were positive for HHV-6 in
serum at least once (28 were positive for the first time at
the basal visit, 5 at the 6-month visit, 2 at the 12-month
visit and 1 at the 18-month visit), while only 3/154 (1.9%)
healthy subjects were positive for HHV-6 in their serum
samples. When we analyzed the MHC2TA mRNA levels in
MS patients with HHV-6 active infection at the basal visit
(28/154; NR=0.6, 1, 1.2, 1.5, 1.9, for the basal visit and 6,
12, 18 and 24 months later, respectively) and those without
HHV-6 active infection at the basal visit (126/154; NR=1.6,
1.4, 1.6, 1.9, 2.2, for the basal visit and 6, 12, 18 and 24
months later, respectively), we found a statistical significant
difference for the NRs at the basal visit (p =0.012), but not
for the other scheduled visits, when MS patients were
under IFN-beta treatment (Figure 1C); MS patients with
HHV-6 active infection were normalized with healthy
subjects with HHV-6 active infection, and MS patients
without HHV-6 active infection were normalized with
healthy subjects without HHV-6 active infection. No stat-
istical significant differences were found in NAbs preva-
lence among MS patients with and without HHV-6 at
basal visit. At table 1 we show the evolution of the
HHV-6 DNA prevalence in the serum along the five
scheduled visits. When we analyzed all the positive sam-
ples, we only found variant A.
Finally, when we analyzed the relationship between the
increase/decrease of MHC2TA expression levels and the
presence/absence of HHV-6 in serum with the clinical
response to IFN-beta treatment (see Table 2), we found
a statistical significant difference: only 5/21 (23.8%) MS
patients with at least one HHV-6 positive serum sample
among the five programmed visits and with a decrease
of the MHC2TA mRNA levels after two years of IFN-
beta treatment were clinical responders, vs. 58/99
(58.6%) MS patients without HHV-6 in the five pro-
grammed visits and with an increase of the MHC2TA
level after two years of IFN-beta treatment (p = 0.004).s
12M 18M 24M




Table 2 Clinical response to IFN-beta treatment in MS patients with a decrease of MHC2TA mRNA levels and HHV-6 in
serum (at least once among the five programmed visits) vs. MS patients with an increase of MHC2TA mRNA level and
without HHV-6 in serum, after two years of IFN-beta treatment
IFN-beta clinical response EDSS* Relapses**
N Resp. %
MHC2TA mRNA level decreased + HHV-6 in serum 21 5 23.8 1.5 1.2
MHC2TA mRNA level increased without HHV-6 in serum 99 58 58.6 - 0.5 0.4
p 0.004
* Mean (EDSS at 24-month minus EDSS at basal visit).
** Mean of relapses after two years of IFN-beta treatment.
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IFN-beta is one of the therapeutic options of relapsing
remitting MS to date, but basic mechanisms underlying
the beneficial effects of IFN-beta are still under investi-
gation [8]. Interferons play essential roles in the front
line of host defense against viral infections and in immu-
nosurveillance for malignant cells. In general, it has been
described that IFN-beta is a far less potent inducer of
MHCII than IFN-gamma [9]. Our results show a light
increase of the MHC2TA mRNA levels from the basal
visit (prior starting IFN-beta treatment) to the 24-month
visit (Figure 1A), but we did not find any statistical sig-
nificant difference (p = 0.134). However, this was a het-
erogeneous population with different polymorphisms at
the MHC2TA gene, with MS patients with and without
viral infections along the two-year IFN-beta treatment,
and with different clinical behavior (we found MS
patients that were clinical responders to IFN-beta and
other MS patients not). Therefore, we analyzed the con-
tribution of each one of these factors to the observed
changes in the MHC2TA mRNA levels.
As we have previously mentioned, all the MS patients
included in the study were characterized for the exonic
rs4774 polymorphism in the MHC2TA gene, and they
were classified as carriers of the minor allele C or car-
riers of the allele G. As we can see in Figure 1B, we did
not find any difference between these two MS popula-
tions. The amino acid change (from alanine to glycine)
brought about by the rs4774C allele seems to be not
related to a different expression pattern of the MHC2TA
gene, but in this study we did not analyze the MHC2TA
protein levels or the effectiveness of this protein as class
II transactivator. Further studies should be performed to
clarify this question.
MHC2TA plays a critical role in the control of anti-
viral immune response [10] and encodes the class II
transactivator, MHC2TA, which is essential for class II
transcription and expression [11]. As a master regulator
of MHC class II genes, MHC2TA is an attractive target
for modulation by pathogens that are controlled by CD4+
T cells [12]. Among such pathogens, Human Parainflu-
enza Virus Type 3 [13], or human cytomegalovirus
(HCMV) (another human beta-herpesvirus such asHHV-6) are able to suppress induction of class II MHC
expression that results in decreased levels of MHC2TA
mRNA levels [14-16]. When we analyzed the effect of the
HHV-6 infection over the expression of the MHC2TA
gene, we found a statistical significant difference
(p= 0.012) between the MHC2TA mRNA levels among
those MS patients that were positive for this virus at the
basal visit (lower expression level) and those that were
negative (higher expression level). The differences were no
longer statistically significant as IFN-beta treatment pro-
gressed. Although it should be further studied, HHV-6
seems to be able to reduce MHC2TA expression; then, the
antiviral effect of IFN-beta treatment, that has been previ-
ously described, among others [17], by our group [18],
leads to a decrease in the HHV-6 active replication rate,
and an observed increasing of the MHC2TA mRNA levels
under the progressive absence of HHV-6 in the serum
along the scheduled visits (see Table 1). Finally, these last
results were related to the clinical response to IFN-beta
treatment (see Table 2): 58/99 (58.6%) MS patients with an
increase of MHC2TA mRNA levels and without HHV-6
in the five programmed visits were free of progression an
relapses under IFN-beta treatment, while only 5/21
(23.8%) of those MS patients with a decrease of MHC2TA
expression and with HHV-6 in at least one of the five pro-
grammed visits could be consider as clinical responder.Conclusions
Then, we can conclude that MHC2TA expression
seems to be lightly influenced by IFN-beta treatment
(through the activation of an antiviral mechanism or
cascade?). The rs4774 polymorphism in the
MHC2TA gene does not seem to have any influence
in the MHC2TA mRNA levels, but it could be
further studied as a possible marker of clinical
response to IFN-beta treatment. Finally, as previously
described for other herpesvirus, like cytomegalovirus,
MHC2TA mRNA levels could be also decreased by
the active replication of HHV-6; the absence
of HHV-6 in serum and the increase of MHC2TA
expression could be further studied as markers of a
good clinical response to IFN-beta treatment.
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